Table 2 Comparison of ≥ Grade 3 toxicities rates between irinotecan-containing doublet versus irinotecan monotherapy
Adverse events | Irinotecan-containing doublet event/total (%) | Irinotecan monotherapy event/total (%) |
|---|---|---|
Neutropenia | 142/425 (33.4) | 128/483 (26.5) |
Anemia | 68/425 (16.0) | 36/483 (7.45) |
Thrombocytopenia | 9/395 (2.3) | 9/454 (2.0) |
Diarrhea | 17/425 (4.0) | 22/483 (4.6) |
Nausea | 21/373 (5.6) | 25/430 (5.8) |
Vomiting | 6/267 (2.2) | 8/272 (2.9) |
Anorexia | 47/425 (11.0) | 50/483 (10.4) |
Fatigue | 16/395 (4.1) | 17/454 (3.7) |